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Background. Pediatric bacterial meningitis (PBM) causes severe morbidity and mortality within Togo. Thus, as a member of 
the World Health Organization coordinated Invasive Bacterial Vaccine Preventable Diseases network, Togo conducts surveillance 
targeting Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus influenzae, at a sen-
tinel hospital within the capital city, Lomé, in the southernmost Maritime region.
Methods. Cerebrospinal fluid was collected from children <5 years with suspected PBM admitted to the Sylvanus Olympio Teaching 
Hospital. Phenotypic detection of pneumococcus, meningococcus, and H. influenzae was confirmed through microbiological techniques. 
Samples were shipped to the Regional Reference Laboratory to corroborate results by species-specific polymerase chain reaction.
Results. Overall, 3644 suspected PBM cases were reported, and 98 cases (2.7%: 98/3644) were confirmed bacterial menin-
gitis. Pneumococcus was responsible for most infections (67.3%: 66/98), followed by H. influenzae (23.5%: 23/98) and meningo-
coccus (9.2%: 9/98). The number of pneumococcal meningitis cases decreased by 88.1% (52/59) postvaccine introduction with 59 
cases from July 2010 to June 2014 and 7 cases from July 2014 to June 2016. However, 5 cases caused by nonvaccine serotypes were 
observed. Fewer PBM cases caused by vaccine serotypes were observed in infants <1 year compared to children 2–5 years.
Conclusions. Routine surveillance showed that PCV13 vaccination is effective in preventing pneumococcal meningitis among 
children <5 years of age in the Maritime region. This complements the MenAfriVac vaccination against meningococcal serogroup 
A to prevent meningitis outbreaks in the northern region of Togo. Continued surveillance is vital for estimating the prevalence of 
PBM, determining vaccine impact, and anticipating epidemics in Togo.
Keywords. Pneumococcus; meningitis; vaccine impact; pediatric; Togo.
In 2014, the World Health Organization (WHO) reported that 
bacterial meningitis epidemics affect approximately 400 million 
people living within the geographical region of Africa known 
as the “meningitis belt” [1]. Togo is situated in West Africa, be-
tween Ghana and Benin, located in the heart of the meningitis 
belt. In 2016, the northern region of the country experienced 
a bacterial meningitis outbreak, with a reported 1975 cases 
and a consequent 127 deaths [2]. Moreover, between January 
and February 2017, more than 250 suspected cases of menin-
gitis were reported in Togo, with 20 deaths and at least 14 cases 
confirmed to be caused by bacterial pathogens [2]. The 3 most 
common pathogens implicated in bacterial meningitis cases 
can be prevented by vaccination: Streptococcus pneumoniae 
(Pneumococcus), Haemophilus influenzae type b (Hib), and 
Neisseria meningitidis (meningococcus) [3–6].
Vaccines targeting pneumococcus, meningococcus, and Hib 
are effective at reducing both the morbidity and mortality asso-
ciated with childhood bacterial meningitis [6, 7]. Consequently, 
various formulations of the pneumococcal conjugate vaccine 
(PCV), meningococcal conjugate vaccine (MenAfriVac), and 
Hib vaccine have been rolled out in the 26 countries contained 
within the extended meningitis belt with funding from Gavi The 
Vaccine Alliance and the Meningitis Vaccine Project (MVP) 
[8–11]. The implementation of these routine conjugate vaccine 
programs has been hugely successful in reducing the burden 
of invasive bacterial disease [12]. As a WHO Collaborating 
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Center for New Vaccines Surveillance (WHO CC NVs) for new 
vaccines surveillance in the West African region of the Invasive 
Bacterial Vaccine Preventable Disease (IB-VPD) network, the 
Medical Research Council Unit The Gambia at the London 
School of Hygiene and Tropical Medicine (MRCG at LSHTM), 
provides laboratory support for pediatric bacterial meningitis 
(PBM) surveillance in 10 countries and 17 sentinel hospitals 
across West and Central Africa.
In July 2008, Togo introduced a pentavalent vaccine against 
diphtheria, whooping cough, tetanus, hepatitis B, and Hib 
into the Expanded Program on Immunization (EPI), which is 
administered in 3 doses to infants at 6, 10, and 14 weeks after 
birth [13]. Coverage rates for the pentavalent vaccine, estimated 
by the WHO and United Nations Children’s Fund (UNICEF), 
have been increasing annually, reaching 90% in 2017 [14]. The 
pivotal role of pneumococcus in contributing to bacterial men-
ingitis cases was highlighted in a study investigating the burden 
of disease in Northern Togo prior to the PCV introduction [15]. 
A second study evaluated pneumococcal serotype distribution 
within Togo from 2007 to 2009 and found that the 10-valent 
and 13-valent PCVs incorporated up to 53% of the serotypes 
responsible for PBM cases [16].
Thus, in 2014, introduction of the 13-valent PCV (PCV13) 
targeting 13 invasive pneumococcal serotypes (1, 3, 4, 5, 6A, 
6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), has prevented pneumo-
coccal meningitis epidemics within the country [16, 17]. PCV13 
is also administered to infants in 3 doses at 6, 10, and 14 weeks 
after birth, and the WHO and UNICEF immunization coverage 
estimates are also encouraging, reporting 90% coverage in 2017 
[13, 14]. Additionally, in 2014, Togo was part of a vaccination 
campaign with the MenAfriVac, providing coverage for up to 
85% of children at risk of invasive bacterial disease (IBD) [2]. 
In addition, during the recent outbreak of 2016, Gavi provided 
MenAfriVac vaccine doses for vaccination of more than 400 000 
people aged under 2 years to 29 years in Togo [18].
Togo is one of the smallest countries in Africa and has a pop-
ulation of approximately 7.6 million people [19]. The human 
immunodeficiency virus (HIV) prevalence in adults aged 
15–49 years is 2.1% with approximately 110 000 adults and chil-
dren living with HIV [20]. Togo is divided into 5 regions, the 
northernmost, bordering with Burkina Faso is the Savanes re-
gion, followed by Kara, Centrale, Plateaux, and the southern-
most, Maritime region, which meets the North Atlantic Ocean 
and is home to the capital city Lomé. Current surveillance of 
bacterial meningitis within Togo show that the heaviest burden 
of disease occurs in the Savanes, Kara, and Centrale regions 
[21]. However, the outbreak in early 2017, caused by menin-
gococcus (serogroup W), was localized to the Plateaux region 
[2]. Meningitis surveillance data are scarce for the Maritime 
Region; therefore, this surveillance site was established to assess 
the prevalence of the most common causes of bacterial men-
ingitis in children aged <5 years here. We report the trends of 
IBD and pathogens detected in samples collected over a 7-year 
period, from 2010 to 2016, as part of efforts to monitor the im-
pact of the PCV13, MenAfriVac, and Hib vaccines within Togo.
METHODS
Surveillance Structure and Design
Routine surveillance of children <5  years of age admitted to 
the Sylvanus Olympio University Hospital Center (CHU SO) 
in Lomé with suspected bacterial meningitis, was carried out 
from 2010 to 2016. During analysis, July 2010 to June 2014 was 
considered the prevaccine period and July 2014 to June 2016 
the postvaccine period for both the PCV13 and MenAfriVac 
vaccination. As the Hib vaccine was introduced in Togo prior 
to this surveillance period, pre- and postvaccine introduction 
comparisons could not be made.
Case Enrollment
Suspected meningitis cases were defined, following WHO 
guidelines, by a sudden onset of fever (>38° C axillary or >38.5° 
C rectal temperatures), in combination with any of the following 
clinical symptoms: altered consciousness, stiffness in the head/
neck, sensitivity to light, and bulging fontanel [22]. Confirmed 
bacterial meningitis cases were defined by the identification of 
pneumococcus, H.  influenzae, or meningococcus in the cere-
brospinal fluid (CSF) of a suspected case [22]. A lumbar punc-
ture (LP) was performed, for children admitted to the CHU SO 
who met the standard case definition, for routine diagnostic 
tests, and CSF collected.
CSF Analysis
Within the CHU SO microbiology laboratory CSF samples 
were processed following the WHO standard operating proce-
dure [22]. Briefly, samples were centrifuged, and the resulting 
bacterial pellet was used to prepare smears for Gram staining. 
Latex agglutination was performed using the supernatant, with 
the Pastorex meningitis kit (Biorad, Watford, UK) for the de-
tection of pneumococcus, H.  influenzae and meningococcus. 
When available, a BINAX® NOW kit (Alere Inc., Waltham, MA 
USA) was used to confirm the presence of pneumococcal an-
tigen. A white blood cell (WBC) count was performed, and pro-
tein and glucose levels were measured using the trichloroacetic 
acid turbidimetric and glucose oxidase methods [23, 24].
A loopful of CSF was streaked directly onto Columbia blood 
agar and chocolate agar plates enriched with 5% defibrillated sheep 
blood. Following overnight incubation, plates were examined for 
characteristic bacterial growth. Suspected pneumococcal isolates 
were confirmed via an optochin test (5 μg optochin disk; Oxoid, 
Basingstoke, UK), whereas suspected H. influenzae and menin-
gococcal isolates underwent an analytical profile index (API NH; 
Biomerieux, Basingstroke, UK). Where possible, serotyping and 
serogrouping for isolates was performed using various latex ag-
glutination techniques, as previously described [25, 26].
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Molecular Analysis
Approximately 1  mL of CSF from positive meningitis cases 
were sent to the MRCG at LSHTM for confirmatory testing. 
Species-specific real-time polymerase chain reaction (RT-PCR) 
assays were conducted with the following gene targets: 
lytA for S.  pneumoniae, hpd for H.  influenzae, and sodC for 
N. meningitidis [3, 27]. The amplification process consisted of 
an initial denaturation step at 95° C (10 minutes), followed by 
45 cycles of 95° C (15 seconds) and 60° C for 1 minute. Samples 
with a cycle threshold (CT) value of ≤36 were considered 
positive.
Serogrouping and Serotyping
For pneumococcal serotyping, CSF of LytA positive samples 
was added to TE buffer containing 0.08  g/mL of lysozyme 
(Sigma-L-6876) and 150 U/mL of mutanolysin (Sigma M-9901) 
and incubated for 1 hour at 37° C. Nucleic acid extraction was 
carried out following Qiagen DNA Mini-kit manufacturer 
instructions and purified DNA underwent sequential triplex 
real-time PCR assay to detect 21 capsular serotypes as described 
elsewhere [28]. Additionally, samples with CT values ≤32 were 
classified as nontypeable and underwent conventional multi-
plex PCR analysis [29]. Meningococcal gene targets included 
sacB, synD, synE, synG, xcbB, synF for serogroups A, B, C, W, 
X, and Y, respectively. For H. influenzae, gene targets included 
acsB, bcsB, ccsD, dscE, ecsH, and bexD for serotypes Hia, Hib, 
Hic, Hid, Hie, and Hif, respectively. CT values of ≤32 were 
considered positive for both meningococcus and H. influenzae 
[30].
Antimicrobial Susceptibility Testing and Whole Genome Sequencing
Antibiotic susceptibility tests were performed on pneumococcal 
isolates via Kirby-Bauer disc diffusion methods, and resistance 
was confirmed via inhibition zones interpreted according to 
the Clinical and Laboratory Standard Institute guidelines [31]. 
The following antibiotics were tested: rifampicin (RD), eryth-
romycin (E), ceftriaxone/cefotaxime (CTX), tetracycline (TE), 
vancomycin (VA), oxacillin (OX), chloramphenicol (C), tri-
methoprim/sulfamethoxazol (SXT), meropenem (MEM), and 
clindamycin (DA).
Genomic DNA was extracted using a modified Qiagen kit 
protocol and sent to the Wellcome Trust Sanger Institute for 
sequencing on an Illumina HiSeq using in-house pipelines 
[32]. Sequencing reads from isolates were mapped onto the 
S. pneumoniae ATCC_700669 serotype 23F reference genome 
using SMALT and pseudo genomes were placed in a multiple 
sequence alignment using custom scripts. Single nucleotide 
polymorphisms (SNPs) were called from the pseudo alignment 
using SNP sites, and a maximum likelihood phylogeny was 
constructed with a general time reversible model using RAxML 
[33]. The phylogenetic tree was visualized and annotated using 
the interactive tree of life (iTol) software [34].
Statistical Analysis
Data were collected at the CHU SO in Lomé using standardized 
WHO Regional Office for Africa (Afro) PBM network case 
report forms. Information recorded included patient dem-
ographics, clinical symptoms, vaccination history, and lab-
oratory information (CSF microscopy, bacteriological tests, 
genotyping). Data were then added to a WHO Epi Info-based 
customized new-vaccine surveillance data module. Data 
cleaning and analysis were first performed at the CHU SO and 
then sent to national and regional WHO data managers. For 
presentation here, data were analyzed using GraphPad Prism 
8.1.1. Percentages, proportion, means, and standard deviations 
were calculated as appropriate and presented as prose, tables, 
and figures.
Ethical Approval
Ethical approval was not a requirement in Togo for routine men-
ingitis surveillance including drug susceptibility testing of col-
lected. However, informed consent was sought from caregivers 
of the surveillance participants. Additionally, the surveillance 
received overarching ethical approval (SCC1188) by the joint 
MRC/The Gambia Government ethics board that allowed the 
analysis of collected West African isolates at MRCG.
RESULTS
Demographic and Clinical Characteristics
A summary of the demographic and clinical characteristics 
of the children enrolled in this surveillance is shown in Table 
1. A  total of 3644 children <5 years old were admitted to the 
CHU SO with suspected meningitis from 2010 to 2016. From 
these patients, 3546 (97.3%) CSF samples were collected and 
tested at the MRCG at LSHTM. The median age of the patients 
was 22  months (interquartile range: 5–36  months). The 
greatest number of suspected cases were seen in children aged 
24–59 months (46.9%; 1708/3644). Overall, 56.9% (2075/3644) 
of patients were male, and the mortality rate for those with 
suspected meningitis was 6.9% (252/3644).
The clinical characteristics of patients enrolled in sentinel sur-
veillance are detailed in Table 2. In summary, 41 (1.4%: 41/2912) 
children who presented with clear CSF samples had confirmed 
bacterial meningitis. However, a higher proportion of patients 
(57/659:8.6%) with turbid, xanthochromic, and blood-stained 
CSF samples were infected with IBD pathogens. The percentage 
of patients with PBM decreased with WBC count; 45% (36/80) 
patients with a high WBC count (>100 cells/mm3) had PBM 
compared to 10.2% (21/206) and 1.3% (41/3206) of patients 
with WBC counts of >10 to 100 cells/mm3 and ≤10 cells/mm3, 
respectively. More patients with PBM had high levels of protein 
(>100  mg/dL) in their CSF (9.5%:21/241) compared to those 
with low protein levels ≤100 mg/dL (1.5%: 28/1890). However, a 
higher proportion of children with CSF glucose levels of ≤40 g/dL 
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had PBM (11.2%: 21/187) compared to (1.5 %: 30/1944) patients 
with higher lower glucose levels (>40 g/dL).
The case-fatality rate of children with confirmed bacterial 
meningitis admitted to the CHU SO varied depending on the 
causative pathogen. For instance, pneumococcus was respon-
sible for 66 cases of PBM identified during surveillance, and 
from these there was a mortality rate of 25.8% (17/66). However, 
both meningococcus and H. influenzae had lower case fatality 
rates of 11.1% (1/9) and 13.0% (3/23), respectively. The overall 
mortality rate for confirmed bacterial meningitis cases was 
21.4% (21/98).
Distribution of Bacterial Pathogens
The annual number of enrolled suspected meningitis cases 
varied each year, ranging from 298 to 748 between 2010 and 
2016 (Figure 1). The average number of suspected cases annu-
ally was 520.6. The prevalence of PBM in the prevaccine pe-
riod was 2.6% (71/2723) and 2.9% (27/921) in the postvaccine 
period.
Pneumococcus was the major causative agent, accounting 
for 67.3% (66/98) of confirmed PBM cases (Figure 1). In the 
prevaccine period, there were a total of 59 pneumococcal men-
ingitis cases identified with an average of 11.8 cases per year. 
In comparison, from July 2014 onward (post-PCV13 period) 
there were 7 cases of pneumococcal meningitis with an av-
erage of 2.3 cases per year. This amounts to an 88.1% (52/59) 
decrease in the number of pneumococcal meningitis cases seen 
in the postvaccine period compared to the prevaccine period. 
The overall prevalence of pneumococcal meningitis in the 
prevaccine period was 2.2% (59/2723) and declined to 0.8% 
(7/921) post-PCV13 introduction.
Serotype analysis was attempted on 35 pneumococcal 
isolates received at the MRCG at LSHTM. In the pre-PCV13 
period, 2010 to June 2014, serotype analysis was performed on 
30 samples, one was nontypeable by PCR, 27 were caused by 
serotypes targeted by PCV13, and 2 were serotype 15B, which is 
a non-PCV13 strain. Postvaccine introduction, 5 samples were 
Table 2. Summary of Clinical Characteristics of Patients in Relation to Causative Pathogen
  Recruited Tested Pneumococcus Meningococcus Haemophilus influenzae
Characteristic  N n (%) n (%) n (%) n (%)
CSF appearance Clear 2912 2888 (99.2) 18 (0.6) 9 (0.3) 14 (0.5)
Turbid 192 191 (99.5) 42 (21.9) 0 8 (4.1)
Xanthrochromic 108 108 (100.0) 2 (1.9) 0 0
Blood Stained 359 357 (99.4) 4 (1.1) 0 1 (0.3)
Unknown 73 2 (2.7) 0 0 0
White blood cell count (cells/mm3) ≤10 3206 3203 (99.9) 22 (0.7) 4 (0.1) 15 (0.5)
>10 to 100 206 206 (100.0) 14 (6.8) 5 (2.4) 2 (1.0)
>100 80 80 (100.0) 30 (37.5) 0 6 (7.5)
Unknown 152 57 (37.5) 0 0 0
Protein (mg/dL) ≤100 1890 1878 (99.4) 9 (0.5) 7 (0.4) 12 (0.6)
>100 241 241 (100.0) 18 (7.5) 0 5 (2.0)
Unknown 1513 1427 (94.3) 39 (2.7) 2 (0.1) 6 (0.4)
Glucose (g/dL) ≤40 187  186 (99.5) 16 (8.6) 1 (0.5) 4 (2.1)
≥40 1944 1934 (99.5) 11 (0.6) 6 (0.3) 13 (0.67)
Unknown 1513 1426 (94.2) 39 (2.7) 2 (0.1) 6 (0.4)
Total number of suspected cases recruiteda 3644 3546 (97.3) 66 (1.9) 9 (0.25) 23 (0.65)
Abbreviation: CSF, cerebrospinal fluid.
aSuspected cases include cases that were defined as suspected, probable, and confirmed as per World Health Organization case definition guidelines [22].
Table 1. Summary of the Clinical and Demographic Characteristics of 
Suspected Meningitis Cases in Children <5 Years, Maritime Region, Togo, 
2010–2016 (N = 3644)
 
Characteristic
 
Category
Total
n %
Age 0–11 m 1421 39.0
12–23 m 512 14.1
24–59 m 1708 47.0
Unknown 3 0.1
Sex Female 1567 43.0
Male 2075 57.0
Unknown 2 0.1
Antibiotic before admission Yes 593 16.3
No 897 24.6
Unknown 2154 59.1
Outcome diagnosis Meningitis 423 11.6
Pneumonia 170 4.7
Septicemia 21 0.6
Other/multiple 1512 41.5
Unknown 1518 41.7
Outcome Discharged alive 2060 56.5
Died 252 6.9
Unknown 1332 36.6
Case typea Suspected 3644 100.0
aSuspected cases include cases that were defined as suspected, probable, and confirmed 
as per World Health Organization case definition guidelines [22].
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serotyped, 2 were nontypeable by PCR, and the remaining 3 
were caused by PCV13 serotypes 6A and 19F. Prior to PCV13 
introduction, pneumococcal serotype 1 was most commonly 
observed, responsible for 9 PBM cases, followed by 23F, which 
caused 4 cases. Following vaccine introduction, there were 
3 cases of PBM caused by serotypes targeted by the vaccine, 
compared to 27 cases in the prevaccine period.
During surveillance, there were 23 (23.5%) cases of PBM 
caused by H. influenzae species, and serotyping was performed 
for 20 isolates at the MRCG at LSHTM. Hib was responsible 
for 9 (39.1%) cases: 5 cases in 2010, 3 in 2014, and 1 in 2015. 
After 2011, there was a change in H.  influenzae serotype dis-
tribution observed, with Hic responsible for all cases observed 
in 2012 (2/2) and Hie accounting for 71.4% (5/7) of cases in 
2015. Meningococcus was the least prevalent IBD pathogen 
observed throughout the surveillance in Togo, accounting for 
9 (9.2%) PBM cases. Of these, 8 were observed in 2016 and 1 
in 2014; only 1 meningococcal isolate was serogrouped, with a 
nongroupable result.
Antimicrobial Susceptibility and Whole Genome Phylogeny of 
S. pneumoniae
A total of 23 pneumococcal isolates obtained from patient CSF 
samples were whole genome sequenced, including both vaccine 
and nonvaccine serotypes. The phylogeny reveals a close rela-
tionship between strains belonging to the same serotype, partic-
ularly among vaccine serotypes such as serotypes 14, 19F, 23F, 
and 6A (Figure 2). The most common sequence types (STs) in 
the data set were ST303, ST618 of serotype 1, plus ST5547 and 
ST4194 of serotypes 6A and 19F, respectively. The nonvaccine 
serotypes including 15B/15C, 23B, and 11C were isolated 
mainly in the pre-PCV13 era (Figure 2).
There were 16 isolates (69.6%: 16/23) with antibiotic resist-
ance and 6 (26.1%: 6/23) with intermediate resistance to tri-
methoprim/sulfamethoxazole. For tetracycline, there were 18 
(78.2%: 18/23) resistant isolates and 4 (17.4%: 4/23) interme-
diate resistant isolates. There was fewer isolates with resistance 
to oxacillin and erythromycin, 9 (39.1%: 9/23), and 1 (4.4%: 
1/23), respectively (Figure 2).
DISCUSSION
We report data from routine PBM sentinel surveillance carried 
out at the CHU SO in Lomé, Togo, from 2010 to 2016 and pro-
vide data on the impact of PCV13, which was introduced to 
Togo’s EPI in July 2014. We provide evidence of a decline in the 
number of children hospitalized due to pneumococcal menin-
gitis post-PCV13 introduction compared to the prevaccine pe-
riod. For instance, from July 2010 to June 2014 there were 59 
cases (2.2%: 59/2723) of pneumococcal meningitis observed in 
children <5 years at the CHU SO. However, in the post-PCV13 
period from July 2014 until the end of surveillance in June 2016, 
there were 7 cases (0.8%: 7/921) of pediatric pneumococcal 
meningitis, which is an 88.1% (52/59) reduction in cases.
Pneumococcus was the predominant etiologic agent found in 
confirmed meningitis cases within pediatric patients from the 
Maritime region of Togo. The total number of cases caused by 
PCV13 serotypes decreased over the course of surveillance, and 
3 nontypeable (by sequential triplex real-time PCR) serotype 
cases were detected, 1 in 2012 and 2 in July 2014. Widespread 
use of PCVs can markedly reduce carriage of vaccine serotypes 
among both vaccinated and unvaccinated individuals due to 
decreased transmission from the vaccinated population [35, 
36]. Recently, a population based study in The Gambia showed 
that the incidence of PCV13 serotype invasive pneumococcal 
disease has reduced significantly, from >200 cases/105 to <50 
cases/105 in children aged 2–23 months [7, 37]. Here we report 
similar findings; a reduction in the number of pneumococcal 
meningitis cases observed in children <59  months in Lomé, 
Togo, after the introduction of PCV13.
However, throughout our surveillance, 96.8% (3528/3644) of 
patients PCV13 vaccination status was either not recorded or 
unknown. Thus, none of the patients with confirmed pneumo-
coccal meningitis reported receiving a full 3-dose course of the 
PCV13 vaccine. In fact, the PCV13 vaccination status was not 
recorded for 96.9% (95/98) of the patients with confirmed bac-
terial meningitis. Of the pneumococcal isolates we serotyped, 
45.5% (30/66) were strains that are included in PCV13 and thus 
may have been prevented by immunization. Our findings sup-
port the need to continue widespread vaccination of Togolese 
children against pneumococcus and continue surveillance to 
monitor the burden of vaccine-preventable bacterial meningitis 
Figure 1. Distribution of suspected pediatric bacterial meningitis cases within 
Togolese children <5 years from 2010 to 2016. Proportion of pediatric bacterial men-
ingitis cases caused by Streptococcus pneumoniae (pneumococcus), Haemophilus 
influenzae, and Neisseria meningitidis (meningococcus) seen at the Sylvanus 
Olympio University Hospital Center in Lomé, Togo. The total number of suspected 
meningitis cases (N = 3644) recruited each year during surveillance is indicated by 
a dashed black line.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/69/Supplem
ent_2/S97/5561324 by guest on 17 January 2020
S102 • cid 2019:69 (Suppl 2) • Tsolenyanu et al
and any potential changes in serotype distribution over time. 
Encouragingly, the 2017 WHO and UNICEF national immuni-
zation coverage estimates suggest that coverage rates for PCV13 
are 90% in Togo [14]. Thus, we anticipate that as vaccine cov-
erage increases and herd effect extends to older children and 
adults, there will be even greater declines in pneumococcal 
meningitis cases in the Maritime region of Togo.
Our data show that Hib remains responsible for a number of 
meningitis cases in Togo, despite the use of Hib-containing vac-
cine and high coverage rates [14]. During surveillance, 67.3% 
(2453/3644) of patients with suspected meningitis reported re-
ceiving the Hib vaccine, 103 of these (4.2%: 103/2453) reported 
receiving a full 3-dose course of the vaccine. Of the 98 confirmed 
meningitis cases, 69.4% (68/98) reported receiving at least one 
dose of the Hib vaccine, but 16 of these patients had confirmed 
H. influenzae meningitis. There were 6 cases of Hib meningitis 
confirmed in patients who reported receiving the Hib vaccine; 
however, details of the dates these vaccinations were received 
were unknown, and vaccination history was provided verbally 
by next of kin. Overall, we found post-2011, non-Hib (by se-
quential triplex real-time PCR) serotypes were the most abun-
dant within H. influenzae meningitis cases. Conversely, in 2010, 
we observed the greatest number of Hib confirmed meningitis 
cases over the entire 7-year surveillance period. These findings 
may be due to the routine administration of the Hib-containing 
vaccine within Togo since 2008, leading to a gradual decline 
in the prevalence of Hib and a greater incidence of non-Hib 
serotypes causing meningitis or could be due to case ascertain-
ment and serotyping techniques improving so that non-Hib 
serotype cases are more accurately diagnosed. However, the 
observation of non-Hib cases of paediatric meningitis within 
Togo, 7 years after Hib vaccine introduction, is significant and 
warrants further investigation through continued surveillance 
as the number of Hib cases continues to decline.
Meningococcus was responsible for just 9 cases of PBM over 
the surveillance period within the Maritime region of Togo. 
This result contrasts with reports from the northern and cen-
tral regions of Togo; meningococcus has been responsible for 
consecutive meningitis outbreaks in the Savanes, Kara, and 
Centrale regions [21]. Additionally, in January 2017, meningo-
coccus caused an outbreak in the Plateau region, next to the 
Maritime region where most of the suspected cases originated 
from [38]. This difference in the prevalence of IBD pathogens 
across Togo may be due to geographical, socioeconomic, and 
Figure 2. Maximum likelihood whole genome phylogenetic tree of pneumococcal isolates recovered from cerebrospinal fluid pediatric patients in Togo. The tree shows 
the antibiotic resistance profiles to chloramphenicol (C), trimethoprim/sulfamethoxazol (SXT), tetracycline (TE), oxacillin (OX), and erythromycin (E), of 23 pneumococcal 
isolates obtained from the cerebrospinal fluid of pediatric bacterial meningitis patients at the Sylvanus Olympio University Hospital Center in Lomé, Togo. Listed in the tree 
annotations from left to right are the isolates serotype, multilocus sequence type (blue), and year of collection. The key indicates the vaccine type, vaccine era, phenotypic 
antibiotic resistance, and genotypic antibiotic resistance prediction. A blue dashed line indicates the reference genome (Streptococcus pneumoniae ATCC_700669 serotype). 
Abbreviation: PCV, pneumococcal conjugate vaccine.
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other predisposing factors that are distributed differently in dif-
ferent regions of the country.
Overall, of 3644 of suspected bacterial meningitis cases reported 
during surveillance, only 2.7% (98/3644) were confirmed bacterial 
meningitis. The WHO case definition for suspected meningitis 
includes common symptoms that are often associated with other 
infections, such as severe malaria and viral meningitis, but are still 
recorded as suspected bacterial meningitis [22]. The WHO case 
definition for confirmed bacterial meningitis is much more spe-
cific; hence, the number of confirmed cases here are much lower 
in comparison to suspected cases [22]. During surveillance, we 
focused on 3 major causative agents of bacterial meningitis (pneu-
mococcus, meningococcus, and H.  influenzae); however, there 
are a plethora of other meningeal pathogens that may have been 
responsible for some of the suspected cases we observed. Thus, 
using techniques to identify greater meningeal pathogens such as 
TaqMan array cards may be beneficial for future work.
Limitations
There are some limitations of this surveillance data that may 
affect the interpretation of the findings. For instance, there 
was a lack of detailed clinical and demographic data for a 
large number of patients with suspected meningitis who 
had a lumbar puncture. For example, the mortality rate of 
suspected PBM was 6.9% (252/3644), but the outcome at dis-
charge for 36.6% (1332/3644) patients was not recorded, so the 
number of patients who died may have been higher than re-
ported. Similarly, long-term sequelae were confirmed in <1.0% 
(21/3644) of patients, but 52.7% (1921:3644) were not followed 
up after discharge; thus, the number of patients with long-term 
sequelae may also be higher than reported. Moreover, for 2% 
(73/3644) patients with suspected meningitis, the appearance of 
the CSF sample collected was not recorded. Additionally, only 
2 of these samples (2.7%: 2/73) were tested for the presence of 
bacterial pathogens; thus, the cases of confirmed bacterial men-
ingitis may have been higher than reported.
In addition, the number of samples from suspected cases 
that were sent to the MRCG at LSHTM for molecular analysis 
was lower during the prevaccination period compared to the 
postvaccination period. This could have reduced the quality of 
data available for analysis and could underestimate the number 
of positive cases reported for the earlier period. However, the 
samples were not purposefully selected based on any partic-
ular criteria of the patients, and there was no systematic bias for 
children whose clinical information was collected and whose 
samples were received and tested at the MRCG at LSHTM.
CONCLUSION
Bacterial meningitis due to infection with pneumococcus, menin-
gococcus, and H. influenzae species remains a significant cause of 
mortality and morbidity in the Maritime region of Togo, despite 
the successful introduction of conjugate vaccines. Enhanced sur-
veillance to further examine the impact of vaccination and to 
detect cases of PBM rapidly to avoid outbreaks is recommended 
for early detection of epidemics in other regions of Togo as well 
as the Maritime region. Moreover, the MRCG at LSHTM should 
continue to collaborate with the CHU SO and Togo to enhance 
the quality of data captured in relation to the 3 most prominent 
pathogens causing meningitis in children <5 years of age.
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